These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 1833208

  • 21. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR, Duncan GE, Napier TC, Bondy SC, Iorio LC, Mueller RA.
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [Abstract] [Full Text] [Related]

  • 22. Ethanol administration does not alter dopamine D1 and D2 receptor characteristics in rat brain.
    Hietala J, Salonen I, Lappalainen J, Syvälahti E.
    Neurosci Lett; 1990 Jan 22; 108(3):289-94. PubMed ID: 2137566
    [Abstract] [Full Text] [Related]

  • 23. Binding sites for [3H]SCH 23390 in retina: properties and possible relationship to dopamine D1-receptors mediating stimulation of adenylate cyclase.
    Makman MH, Dvorkin B.
    Brain Res; 1986 Dec 22; 387(3):261-70. PubMed ID: 2950967
    [Abstract] [Full Text] [Related]

  • 24. Anatomical and affinity state comparisons between dopamine D1 and D2 receptors in the rat central nervous system.
    Richfield EK, Penney JB, Young AB.
    Neuroscience; 1989 Dec 22; 30(3):767-77. PubMed ID: 2528080
    [Abstract] [Full Text] [Related]

  • 25. Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum.
    Billard W, Ruperto V, Crosby G, Iorio LC, Barnett A.
    Life Sci; 1984 Oct 29; 35(18):1885-93. PubMed ID: 6387355
    [Abstract] [Full Text] [Related]

  • 26. Striatal dopamine D1-like receptors have higher affinity for dopamine in ethanol-treated rats.
    May T.
    Eur J Pharmacol; 1992 May 14; 215(2-3):313-6. PubMed ID: 1396997
    [Abstract] [Full Text] [Related]

  • 27. Impaired ontogeny of striatal dopamine D1 and D2 binding sites after postnatal treatment of rats with SCH-23390 and spiroperidol.
    Kostrzewa RM, Saleh MI.
    Brain Res Dev Brain Res; 1989 Jan 01; 45(1):95-101. PubMed ID: 2645067
    [Abstract] [Full Text] [Related]

  • 28. Chronic haloperidol does not alter agonist affinity for dopamine receptors in vitro.
    Meller E, Bohmaker K, Goldstein M, Schweitzer JW, Friedhoff AJ.
    Eur J Pharmacol; 1985 Mar 12; 109(3):389-94. PubMed ID: 3157587
    [Abstract] [Full Text] [Related]

  • 29. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
    Hancock AA, Marsh CL.
    Mol Pharmacol; 1984 Nov 12; 26(3):439-51. PubMed ID: 6238230
    [Abstract] [Full Text] [Related]

  • 30. [125]I-spectramide: a novel benzamide displaying potent and selective effects at the D2 dopamine receptor.
    Sánchez-Roa PM, Grigoriadis DE, Wilson AA, Sharkey J, Dannals RF, Villemagne VL, Wong DF, Wagner HN, Kuhar MJ.
    Life Sci; 1989 Nov 12; 45(19):1821-9. PubMed ID: 2531826
    [Abstract] [Full Text] [Related]

  • 31. Serotonergic component of SCH 23390: in vitro and in vivo binding analyses.
    McQuade RD, Ford D, Duffy RA, Chipkin RE, Iorio LC, Barnett A.
    Life Sci; 1988 Nov 12; 43(23):1861-9. PubMed ID: 2904635
    [Abstract] [Full Text] [Related]

  • 32. Regional changes of striatal dopamine receptors following denervation by 6-hydroxydopamine and fetal mesencephalic grafts in the rat.
    Gagnon C, Bédard PJ, Rioux L, Gaudin D, Martinoli MG, Pelletier G, Di Paolo T.
    Brain Res; 1991 Sep 06; 558(2):251-63. PubMed ID: 1838295
    [Abstract] [Full Text] [Related]

  • 33. Comparisons between the in vitro binding of two substituted benzamides and two butyrophenones to dopamine-D2 receptors in the rat striatum.
    Hall H, Wedel I.
    Acta Pharmacol Toxicol (Copenh); 1986 May 06; 58(5):368-73. PubMed ID: 2943136
    [Abstract] [Full Text] [Related]

  • 34. Adaptive mechanisms of striatal D1 and D2 dopamine receptors in response to a prolonged reserpine treatment in mice.
    Rubinstein M, Muschietti JP, Gershanik O, Flawia MM, Stefano FJ.
    J Pharmacol Exp Ther; 1990 Feb 06; 252(2):810-6. PubMed ID: 2138223
    [Abstract] [Full Text] [Related]

  • 35. Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors.
    Hess EJ, Norman AB, Creese I.
    J Neurosci; 1988 Jul 06; 8(7):2361-70. PubMed ID: 2907912
    [Abstract] [Full Text] [Related]

  • 36. Binding characteristics of the dopamine agonist/antagonist [3H]terguride (transdihydrolisuride) in the rat striatum.
    Valchár M, Vrsecká M, Krejcí I, Dlabac A.
    Eur J Pharmacol; 1987 Apr 07; 136(1):97-101. PubMed ID: 3297739
    [Abstract] [Full Text] [Related]

  • 37. Mono- and divalent cations modulate the affinities of brain D1 and D2 receptors for dopamine by a mechanism independent of receptor coupling to guanyl nucleotide binding proteins.
    Urwyler S.
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Apr 07; 339(4):374-82. PubMed ID: 2500603
    [Abstract] [Full Text] [Related]

  • 38. Altered dopamine receptor mediated signal transmission in the striatum of aged rats.
    May T, Sugawa M.
    Brain Res; 1993 Feb 26; 604(1-2):106-11. PubMed ID: 8457839
    [Abstract] [Full Text] [Related]

  • 39. Absence of [3H]SCH 23390 binding sites in the rat adrenal gland.
    Zdilar D, Lacković Z.
    J Pharm Pharmacol; 1989 Sep 26; 41(9):646-8. PubMed ID: 2573713
    [Abstract] [Full Text] [Related]

  • 40. Competitive inhibition of [3H]spiperone binding to D-2 dopamine receptors in striatal homogenates by organic calcium channel antagonists and polyvalent cations.
    De Vries DJ, Beart PM.
    Eur J Pharmacol; 1984 Oct 30; 106(1):133-9. PubMed ID: 6241565
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.